Therapeutic protein-drug interactions: plausible mechanisms and assessment strategies

References

• Glezen TJ, Mantel-Teeuwisse AK, Straus S, et al. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA. 2008;300(16):1887–1896.
   PubMed Web of Science ®Google Scholar
• Weinblatt M, Kremer JM, Bankhurst A, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fcfusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253–259.
   PubMed Web of Science ®Google Scholar
• Lipsky P, van der Heijde D, St. Clair W, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594–1602.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez JJ, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.
   PubMed Web of Science ®Google Scholar
• Vozeh S, Powell JR, Riegelman S, et al. Changes in theophylline clearance during acute illness. JAMA. 1978;240:1882–1884.
   PubMed Web of Science ®Google Scholar
• Kraemer MJ, Furukawa CT, Koup JR, et al. Altered theophylline clearance during an influenza B outbreak. Pediatrics. 1982;69:476–480.
   PubMed Web of Science ®Google Scholar
• Morgan ET. Down-regulation of multiple cytochrome P450 gene products by inflammatory mediators in vivo. Independence from the hypothalamo-pituitary axis. Biochem Pharmacol. 1993;45:415–419.
   PubMed Web of Science ®Google Scholar
• Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev. 1997;29(4):1129–1188.
   PubMed Web of Science ®Google Scholar
• Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009;85(4):434–438.
   PubMed Web of Science ®Google Scholar
• Kacevska M, Robertson GR, Clarke SJ, et al. Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opin Drug Metab Toxicol. 2008;4(2):137–149.
   PubMed Web of Science ®Google Scholar
• Liptrott NJ, Penny M, Bray PG, et al. The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. Br J Pharmacol. 2009 Feb;156(3):497–508.
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41(9):1552–1563.
   PubMed Web of Science ®Google Scholar
• Seitz K, Zhou H. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol. 2007;47(9):1104–1118.
   PubMed Web of Science ®Google Scholar
• Mahmood I, Green MD. Drug interaction studies of therapeutic proteins or monoclonal antibodies. J Clin Pharmacol. 2007;47(12):1540–1554.
   PubMed Web of Science ®Google Scholar
• Lee JI, Zhang L, Men AY, et al. CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. Clin Pharmacokinet. 2010;49(5):295–310.
   PubMed Web of Science ®Google Scholar
• Huang SM, Zhao H, Lee JI, et al. Therapeutic protein-drug interactions and implications for drug development. Clin Pharmacol Ther. 2010;87(4):497–503.
   PubMed Web of Science ®Google Scholar
• Zhou H, Mascelli MA. Mechanisms of monoclonal antibody-drug interactions. Annu Rev Pharmacol Toxicol. 2011;51:359–372.
   PubMed Web of Science ®Google Scholar
• Zhou H, Davis HM. Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies. Drug Discov Today. 2009;14(17–18):891–898.
   PubMed Web of Science ®Google Scholar
• Kenny JR, Liu M, Chow AT, et al. Therapeutic protein drug–drug interactions: navigating the knowledge gaps–highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA Workshop. AAPS J. 2013;15(4):933–940.
   PubMed Web of Science ®Google Scholar
• Pharmacokinetics and Disposition Expert Working Group Drug-Drug Interaction Taskforce, Lloyd P, Zhou H, et al. . Highlights from a recent BIO survey on therapeutic protein-drug interactions. J Clin Pharmacol. 2012;52(11):1755–1763.
   PubMed Web of Science ®Google Scholar
• Evers R, Dallas S, Dickmann LJ, et al. Critical review of preclinical approaches to investigate cytochrome P450–mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white papers. Drug Metab Dispos. 2013;41:1598–1609.
   PubMed Web of Science ®Google Scholar
• Chow AT, Earp JC, Gupta M, et al. Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions. J Clin Pharmacol. 2014;54(5):593–601.
   PubMed Web of Science ®Google Scholar
• Schmitt C, Kuhn B, Zhang X, et al. Disease-drug–drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89(5):735–740.
   PubMed Web of Science ®Google Scholar
• Dallas S, Sensenhauser C, Batheja A, et al. De-risking bio-therapeutics for possible drug interactions using cryopreserved human hepatocytes. Curr Drug Metab. 2012;13(7):923–929.
   PubMed Web of Science ®Google Scholar
• Zhuang Y, de Vries D, Xu Z, et al. Evaluation of disease-mediated therapeutic protein–drug interactions between an anti–Interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach. J Clin Pharmacol. 2015;55(12):1386–1394.
   PubMed Web of Science ®Google Scholar
• Sifontis NM, Benedetti E, Vasquez EM. Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. Transplant Proc. 2002;34:1730–1732.
   PubMed Web of Science ®Google Scholar
• Tran JQ, Othman AA, Wolstencroft P, et al. Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach. Br J Clin Pharmacol. 2016;82:160–167. (Epub ahead of print 2016 Mar 17). doi:10.1111/bcp.12936.
   PubMed Web of Science ®Google Scholar
• Morgan ET, Goralski K, Piquette-Miller M, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Rev. 2008;36(2):205–216.
   Web of Science ®Google Scholar
• Petrovic V, Teng S, Piquette-Miller M. Regulation of drug transporters during infection and inflammation. Mol Interv. 2007;7(2):99–111.
   PubMedGoogle Scholar
• Petrovic V, Kojovic D, Cressman A, et al. Maternal bacterial infections impact expression of drug transporters in human placeta. Int Immunopharmacol. 2015;26:349–356.
   PubMed Web of Science ®Google Scholar
• Cherrington N, Estrada T, Frisk H, et al. The hepatic bile acid transporters Ntcp and Mrp2 are downregulated in experimental necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol. 2013;304(1):G48–G56.
   Google Scholar
• Chen YL, Le Vraux V, Leneveu A, et al. Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther. 1994;55:649–660.
   PubMed Web of Science ®Google Scholar
• Pheterson AD, Miller L, Fox CF, et al. Multifocal neurological impairment caused by infection-induced rise in blood lithium and amitriptyline. Int J Psychiatry Med. 1986-1987;16:257–262.
   PubMed Web of Science ®Google Scholar
• Mayo PR, Skeith K, Russell AS, et al. Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br J Clin Pharmacol. 2000;50:605–613.
   PubMed Web of Science ®Google Scholar
• Michot JM, Van Bambeke F, Mingeot-Leclercq MP, et al. Active efflux of ciprofloxacin from J774 macrophages through an MRP-like transporter. Antimicrob Agents Chemother. 2004;48:2673–2682.
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675–681.
   PubMed Web of Science ®Google Scholar
• Weinblatt M, Keystone E, Furst D, et al. Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35–45.
   PubMed Web of Science ®Google Scholar
• Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71(11):1914–1915.
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-Tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naïve patients with active rheumatoid arthritis. Arthritis Rheum. 2009;60(8):2272–2283.
   PubMed Web of Science ®Google Scholar
• Kropshofer H, Richter WF. Immunogenicity: its impact on ADME of therapeutic biologics. In: Zhou H, Thiel FP, editors. ADME and translational pharmacokinetics/pharmacodynamics of therapeutic proteins - applications in drug discovery and development. Hoboken, NJ: Wiley; 2015. p. 147–158.
   Google Scholar
• Richter WF. Gallati H, Schiller CD. Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans. Drug Metab Dispos. 1999;27(1):21–25.
   PubMed Web of Science ®Google Scholar
• Rojas JR, Taylor RP, Cunningham MR, et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. JPET. 2005;313(2):578–585.
   PubMed Web of Science ®Google Scholar
• Wijngaarden S, van Roon JAG, van de Winkel JGJ, et al. Down-regulation of activating Fc receptors on monocytes of patients with rheumatoid arthritis upon methotrexate treatment. Rheumatology. 2005;44:729–734.
   PubMed Web of Science ®Google Scholar
• Wang W, Leu J, Zhou H. Elucidation of the mechanism of therapeutic protein-drug interaction (TPDI) between methotrexate (MTX) and an anti-TNFα monoclonal antibody (MAB), golimumab. Clin Pharm Ther. 2015;97(Suppl 1):S1–S116.
   Google Scholar
• Pastuskovas C, Mundo E, Williams S, et al. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther. 2013;11(3):752–762.
   Web of Science ®Google Scholar
• Abuqayyas L, Balthasar J. Pharmacokinetic mAb-mAb interaction: anti-VEGF mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenografts. AAPS J. 2012;14(3):445–455.
   PubMed Web of Science ®Google Scholar
• Thomas V, Balthasar J. Sorafenib decreases the tumor uptake and distribution of an anti-carcinoembryonic antigen monoclonal antibody in a mouse model of colorectal cancer. AAPS J. Epub 2016 Mar 30. doi:10.1208/S12248-016-9909-Y.
   Web of Science ®Google Scholar
• Struemper H, Sale M, Patel B, et al. Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. J Clin Pharmacol. 2014;54(7):818–827.
   PubMed Web of Science ®Google Scholar
• Garrett M, Ruiz A, Parivar K, et al. Characterization of inotuzumab ozogamicin time-dependent clearance in relapsed/refractory acute lymphoblastic leukemia patients by nonlinear mixed-effects analysis. Clin Pharmacol Ther. 2016;99(Suppl 1):S5–S107.
   Google Scholar
• Yu Z, Lennon V. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med. 1999;340:227–228.
   PubMed Web of Science ®Google Scholar
• Hansen R, Balthasar J. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost. 2002;88:898–899.
   PubMed Web of Science ®Google Scholar
• Garg A, Balthasar J. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007;34:687–709.
   PubMed Web of Science ®Google Scholar
• Flaman A, Gravel C, Hashem A, et al. The effect of interferon-α on the expression of cytochrome P450 3A4 in human hepatoma cells. Toxicol Appl Pharmacol. 2011;253:130–136.
   PubMed Web of Science ®Google Scholar
• Brennan B, Xu Z, Grippo J. Effect of peginterferon alfa-2a (40kd) on cytochrome P450 isoenyme activity. Br J Clin Pharmacol. 2013;75(2):497–506.
   PubMed Web of Science ®Google Scholar
• Calleja C, Eeckhoutte C, Larrieu G, et al. Differential effects of interleukin-1β, interleukin-2, and interferon-γ on the inducible expression of CYP 1A1 and CYP 1A2 in cultured rabbit hepatocytes. Biochem Biophys Res Commun. 1997;239:273–278.
   PubMed Web of Science ®Google Scholar
• Yang B, Gillespie B, Smith B, et al. Pharmacokinetic and pharmacodynamics interactions between palifermin and heparin. J Clin Pharmacol. 2015;55(10):1109–1118.
   PubMed Web of Science ®Google Scholar
• Machavaram K, Almond L, Rostami-Hodjegan A, et al. A Physiologically based pharmacokinetic modeling approach to predict disease–drug interactions: suppression of CYP3A by IL-6. Clin Pharmacol Ther. 2013;94:260–268.
   PubMed Web of Science ®Google Scholar
• Jiang X, Zhuang Y, Xu Z, et al. Development of a physiologically based pharmacokinetic model to predict disease-mediated therapeutic protein–drug interactions: modulation of multiple cytochrome P450 enzymes by interleukin-6. AAPS J. 2016. Epub 2016 Mar 9. doi:10.1208/s12248-016-9890-5.
   Web of Science ®Google Scholar
• Xu Y, Hijazi Y, Wu B, et al. Physiologically based pharmacokinetic model to assess the influence of blinatumomab-mediated cytokine elevations on cytochrome P450 enzyme activity. CPT PSP. 2015;4(9):507–515.
   Google Scholar
• Passey C, Simon J, Hong Q, et al. Assessment of drug interaction potential by nivolumab using cytokine modulation data. Clin Pharm Ther. 2015;97(Suppl 1):S96.
   Google Scholar
• Wei X, Kenny J, Dickmann L, et al. Assessment of disease related therapeutic protein drug–drug interaction for etrolizumab in patients with moderately to severely active ulcerative colitis. J Clin Pharmacol. Epub 2016 Jan 11. doi:10.1002/jcph.649.
   Web of Science ®Google Scholar
• Wang J, Wang Y, Ahn H. Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications. AAPS J. 2014;16(5):938–947.
   PubMed Web of Science ®Google Scholar
• Jonsson-Schmunk K, Wonganan P, Choi J, et al. Integrin receptors play a key role in the regulation of hepatic CYP3A. Drug Metab Dispos. 2016;44:758–770.
   PubMed Web of Science ®Google Scholar
• USPI for Adalimumab (Humira). AbbVie, Inc; 2015 Nov.
   Google Scholar